Evidence map›Paper›PMID 38971694›Full record

ArticleOral surgery, oral medicine, oral pathology and oral radiology2024

Establishment and characterization of cMYB-expressing human salivary adenoid cystic carcinoma cell lines (UM-HACC-14, UM-HACC-6) and matching patient-derived xenograft model (UM-PDX-HACC-14).

Kristy A Warner, Alexandra E Herzog, Sosuke Sahara, Felipe Nör, Rogerio M Castilho, Hakan Demirci, Douglas B Chepeha, Peter J Polverini, Jacques E Nör

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oral surgery, oral medicine, oral pathology and oral radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kristy A WarnerDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI, USA.
Alexandra E HerzogDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI, USA.
Sosuke SaharaDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI, USA.
Felipe NörDepartment of Periodontics and Oral Medicine, School of Dentistry, Ann Arbor, MI, USA.
Rogerio M CastilhoDepartment of Periodontics and Oral Medicine, School of Dentistry, Ann Arbor, MI, USA.
Hakan DemirciDepartment of Opthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA.
Douglas B ChepehaDepartment of Otolaryngology, University of Toronto, Toronto, ON, Canada.
Peter J PolveriniDepartment of Otolaryngology, University of Michigan School of Medicine, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA; Department of Periodontics and Oral Medicine, School of Dentistry, Ann Arbor, MI, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Jacques E NörDepartment of Cariology, Restorative Sciences, Endodontics, University of Michigan School of Dentistry, Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan College of Engineering, Ann Arbor, MI, USA; Department of Otolaryngology, University of Michigan School of Medicine, Ann Arbor, MI, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA. Electronic address: jenor@umich.edu.

Funding

Salivary gland cancer stem cellsR01DE021139 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jacques Eduardo Nor · 2011 to 2026
$5.8M
Therapeutic Inhibition of MDM2/Bcl-2 in Pre-clinical Models of Adenoid Cystic CarR01DE023220 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NOR, JACQUES EDUARDO · 2012 to 2015
$1.5M
NIDCR NIH HHS R01 DE021139NIDCR NIH HHS R01 DE023220
6 · The paper itself

Abstract

objectiveLimited availability of authentic human adenoid cystic carcinoma (ACC) cell lines has hindered progress in understanding mechanisms underpinning the biology of this disease and the development of safe and effective therapies. STUDY

designSurgical human ACC specimens (UM-HACC-6, UM-HACC-14) were dissociated into single cell suspensions and cultured in fibronectin-coated flasks. Alternatively, tumor fragments were transplanted subcutaneously into female immunodeficient (SCID) mice to establish patient-derived xenograft tumors (PDX; UM-PDX-HACC-14).

resultsBoth ACC cell lines showed continuous growth in monolayers for over 100 passages. Total RNA-Seq, RT-PCR, and FISH analysis revealed that both are MYB-NFIB fusion negative. Western blots revealed passage-dependent expression of E-Cadherin, PCNA, p63, phospho-c-MYB, and NFIB. Both, UM-HACC-14 and UM-HACC-6 cells exhibited tumorigenic potential when injected orthotopically into mouse submandibular glands.

conclusionUM-HACC-14, patient-matching UM-PDX-HACC-14, and the UM-HACC-6 cell line are new, authenticated preclinical models of ACC that are well suited for mechanistic and developmental therapeutics studies.

Indexed as

Carcinoma, Adenoid CysticMice, SCIDSalivary Gland NeoplasmsAnimalsBlotting, WesternCell Line, TumorFemaleHeterograftsHumansIn Situ Hybridization, FluorescenceMice

Identifiers

PMID38971694
PMCPMC11827064

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.